capivasertib (Truqap) plus abiraterone and prednisone: FDA status

Approved Approved Jun 12, 2026. Indication: PTEN deficient metastatic hormone sensitive prostate cancer. Company: AstraZeneca.

Regulatory history

• Jun 12, 2026: Approved. FDA approved capivasertib plus abiraterone and prednisone for metastatic prostate cancer. The ASCO Post
• Apr 30, 2026: Advisory committee. FDA ODAC voted in favor of capivasertib plus abiraterone in PTEN deficient mHSPC Urology Times

All products in the FDA Tracker